Somdyuti Das, School of Law, Bennett University
ABSTRACT
Patent evergreening, a contentious pharmaceutical company practise, has generated worries about innovation and cheap drug availability. This study discusses patent evergreening, the strategic extension of patent protection for small medicinal advancements, and its possible effects. The study examines patent evergreening's ethical, legal, and economic implications, examining both proponents and detractors. The report also discusses how patent evergreening may stifle competition, raise medication costs, and restrict generic pharmaceutical supply. The report also covers legislative improvements, court judgements, and international agreements to avoid patent evergreening. Finally, the report emphasises the need for balanced policies that support real innovation while protecting patient access to inexpensive medications and investigates patent evergreening preventive strategies. This article discusses patent evergreening's ramifications and possible remedies to guarantee pharmaceutical innovation and cheap medical access.
Comments